The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC).
Matteo Simonelli
No relevant relationships to disclose
Paolo A. Zucali
No relevant relationships to disclose
Melanie B. Thomas
No relevant relationships to disclose
Alan Brisendine
No relevant relationships to disclose
Jordan Berlin
Research Funding - Pfizer
Cristina Noberasco
No relevant relationships to disclose
Crystal Shereen Denlinger
Consultant or Advisory Role - MedImmune; Pfizer; Vicus Therapeutics
Research Funding - AstraZeneca; ImClone Systems; MedImmune; Merrimack; Morphotek; Pfizer
Tae-You Kim
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Corrado Gallo-Stampino
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Marina Carpentieri
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Erjian Wang
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
James Andrew Williams
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Filippo G. De Braud
Research Funding - Pfizer